Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now full pipeline small index

Refractory Chronic Cough: full-pipeline trial registry

4 of 6 indexed Refractory Chronic Cough trials are currently recruiting.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · 4 currently recruiting · #2,866 of 28,707 conditions by registered trial count

Refractory Chronic Cough: 6 US clinical trials tracked, 4 recruiting.

Refractory Chronic Cough is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Bellus Health Inc. - a GSK company, running 2 of these trials.

Enrollment posture brief

Registry condition refractory-chronic-cough

OPEN 4 | RECR 67% | LATE 2 | EARLY 3 | RANK #2866 | SPON 2

Nearest open-share peer: Adenocarcinoma of Lung (67% recruiting · 6 trials)

Refractory Chronic Cough (th…67%Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%
Open-enrollment share among volume-matched conditions near Refractory Chronic Cough

Refractory Chronic Cough lists 4 open slots (67% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Refractory Chronic Cough on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Refractory Chronic Cough is recruiting above its size-band peers.

    4 of 6 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Refractory Chronic Cough research.

    Bellus Health Inc. - a GSK company accounts for 2 of 6 trials (33.3%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Most Refractory Chronic Cough trials plan to enrol fewer than 100 people.

    Median target enrolment is 60 among the 6 trials that report a genuine target (sentinel values excluded). 4 of those (66.7%) plan for fewer than 100 participants.

  4. Refractory Chronic Cough research is mostly interventional.

    6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 21Phase 32

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 1
Phase 3 2

Top Sponsors

Named interventions

Most-linked intervention names on Refractory Chronic Cough records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

BLU-5937 Drug
2 trials
Placebo Drug
2 trials
6 mg NOC-110 (via DPI) Drug
1 trials
Placebo (via DPI) Drug
1 trials
3 mg NOC-110 (via DPI) Drug
1 trials
1 mg NOC-110 (via DPI) [1x 1 mg capsule] Drug
1 trials
3 mg NOC-100 (via nebulizer) Drug
1 trials
Placebo 30 MG Drug
1 trials

US sites by state

Facility locations filed on Refractory Chronic Cough trials. A trial with sites in several states counts in each.

Florida 3 trials
Arizona 3 trials
Georgia 2 trials
Colorado 2 trials
California 2 trials
Montana 1 trials
Minnesota 1 trials
Illinois 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Refractory Chronic Cough page

6 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Refractory Chronic Cough condition card totals 6 registered trials; most-linked intervention BLU-5937; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.